Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges

Overview

Journal Contrast Media Mol Imaging

Specialty Radiology

Date 2017 Nov 4

PMID 29097933

Citations 46

Authors

Junfeng Zhang

Heng Liu

Haipeng Tong

Sumei Wang

Yizeng Yang

Gang Liu

Weiguo Zhang

Affiliations

Soon will be listed here.

Abstract

Gliomas possess complex and heterogeneous vasculatures with abnormal hemodynamics. Despite considerable advances in diagnostic and therapeutic techniques for improving tumor management and patient care in recent years, the prognosis of malignant gliomas remains dismal. Perfusion-weighted magnetic resonance imaging techniques that could noninvasively provide superior information on vascular functionality have attracted much attention for evaluating brain tumors. However, nonconsensus imaging protocols and postprocessing analysis among different institutions impede their integration into standard-of-care imaging in clinic. And there have been very few studies providing a comprehensive evidence-based and systematic summary. This review first outlines the status of glioma theranostics and tumor-associated vascular pathology and then presents an overview of the principles of dynamic contrast-enhanced MRI (DCE-MRI) and dynamic susceptibility contrast-MRI (DSC-MRI), with emphasis on their recent clinical applications in gliomas including tumor grading, identification of molecular characteristics, differentiation of glioma from other brain tumors, treatment response assessment, and predicting prognosis. Current challenges and future perspectives are also highlighted.

Citing Articles

Current trends in the characterization and monitoring of vascular response to cancer therapy.

Shrestha B, Stern N, Zhou A, Dunn A, Porter T Cancer Imaging. 2024; 24(1):143.

PMID: 39438891 PMC: 11515715. DOI: 10.1186/s40644-024-00767-8.

"Synthetic" DSC Perfusion MRI with Adjustable Acquisition Parameters in Brain Tumors Using Dynamic Spin-and-Gradient-Echo Echoplanar Imaging.

Sanvito F, Yao J, Cho N, Raymond C, Telesca D, Pope W AJNR Am J Neuroradiol. 2024; 46(2):311-320.

PMID: 39242197 PMC: 11878977. DOI: 10.3174/ajnr.A8475.

Review of tracer kinetic models in evaluation of gliomas using dynamic contrast-enhanced imaging.

Zhou J, Hou Z, Tian C, Zhu Z, Ye M, Chen S Front Oncol. 2024; 14:1380793.

PMID: 38947892 PMC: 11211364. DOI: 10.3389/fonc.2024.1380793.

Long-term Intravital Investigation of an Orthotopic Glioma Mouse Model Optical Coherence Tomography Angiography.

Zheng K, Wang G, Zhou K, Wen X, Zhou Y, Ling S In Vivo. 2024; 38(3):1192-1198.

PMID: 38688651 PMC: 11059891. DOI: 10.21873/invivo.13554.

An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI.

Garcia-Ruiz A, Pons-Escoda A, Grussu F, Naval-Baudin P, Monreal-Aguero C, Hermann G Cell Rep Med. 2024; 5(3):101464.

PMID: 38471504 PMC: 10983037. DOI: 10.1016/j.xcrm.2024.101464.

References

Fan Q, Cheng C, Gustafson W, Charron E, Zipper P, Wong R . EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 2013; 24(4):438-49. PMC: 3819146. DOI: 10.1016/j.ccr.2013.09.004. View

Ahn S, Shin N, Chang J, Kim S, Kim E, Kim D . Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging. J Neurosurg. 2014; 121(2):367-73. DOI: 10.3171/2014.5.JNS132279. View

Toh C, Wei K, Chang C, Ng S, Wong H . Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction. AJNR Am J Neuroradiol. 2013; 34(6):1145-9. PMC: 7964581. DOI: 10.3174/ajnr.A3383. View

Khan M, Sharma A, Pitz M, Loewen S, Quon H, Poulin A . High-grade glioma management and response assessment-recent advances and current challenges. Curr Oncol. 2016; 23(4):e383-91. PMC: 4974045. DOI: 10.3747/co.23.3082. View

Gutman D, Cooper L, Hwang S, Holder C, Gao J, Aurora T . MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology. 2013; 267(2):560-9. PMC: 3632807. DOI: 10.1148/radiol.13120118. View

Goodenberger M, Jenkins R . Genetics of adult glioma. Cancer Genet. 2012; 205(12):613-21. DOI: 10.1016/j.cancergen.2012.10.009. View

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2012; 31(3):337-43. PMC: 3732012. DOI: 10.1200/JCO.2012.43.2674. View

Whittle I . The dilemma of low grade glioma. J Neurol Neurosurg Psychiatry. 2004; 75 Suppl 2:ii31-6. PMC: 1765658. DOI: 10.1136/jnnp.2004.040501. View

ONeill A, Qin L, Wen P, de Groot J, Van Den Abbeele A, Yap J . Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016; 130(3):495-503. DOI: 10.1007/s11060-016-2243-5. View

10.

Just N . Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer. 2014; 111(12):2205-13. PMC: 4264439. DOI: 10.1038/bjc.2014.512. View

11.

Diehn M, Nardini C, Wang D, McGovern S, Jayaraman M, Liang Y . Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A. 2008; 105(13):5213-8. PMC: 2278224. DOI: 10.1073/pnas.0801279105. View

12.

Gupta A, Young R, Shah A, Schweitzer A, Graber J, Shi W . Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification. Clin Neuroradiol. 2014; 25(2):143-50. PMC: 4712066. DOI: 10.1007/s00062-014-0289-3. View

13.

Bertolino N, Marchionni C, Ghielmetti F, Burns B, Finocchiaro G, Anghileri E . Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study. Phys Med. 2014; 30(6):702-7. DOI: 10.1016/j.ejmp.2014.03.002. View

14.

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

15.

Peet A, Arvanitis T, Leach M, Waldman A . Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol. 2012; 9(12):700-11. DOI: 10.1038/nrclinonc.2012.187. View

16.

Ellingson B, Wen P, van den Bent M, Cloughesy T . Pros and cons of current brain tumor imaging. Neuro Oncol. 2014; 16 Suppl 7:vii2-11. PMC: 4195528. DOI: 10.1093/neuonc/nou224. View

17.

Riemenschneider M, Hegi M, Reifenberger G . MGMT promoter methylation in malignant gliomas. Target Oncol. 2010; 5(3):161-5. DOI: 10.1007/s11523-010-0153-6. View

18.

Omuro A, Leite C, Mokhtari K, Delattre J . Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006; 5(11):937-48. DOI: 10.1016/S1474-4422(06)70597-X. View

19.

Schmainda K, Prah M, Connelly J, Rand S, Hoffman R, Mueller W . Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol. 2014; 16(6):880-8. PMC: 4022214. DOI: 10.1093/neuonc/not216. View

20.

OConnor J, Tofts P, Miles K, Parkes L, Thompson G, Jackson A . Dynamic contrast-enhanced imaging techniques: CT and MRI. Br J Radiol. 2012; 84 Spec No 2:S112-20. PMC: 3473907. DOI: 10.1259/bjr/55166688. View